NewAmsterdam Pharma (NAMS) Earnings Date, Estimates & Call Transcripts $16.34 +0.31 (+1.93%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$16.30 -0.04 (-0.21%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NewAmsterdam Pharma Earnings Summary Upcoming Earnings DateMay. 14Before Market OpensEstimatedConsensus EPS (Feb. 26) -$0.48 Actual EPS (Feb. 26) -$0.95 Missed By -$0.47 Actual Revenue (Feb. 26) $12.77MNewAmsterdam Pharma posted Q4 2024 earnings on February 26, 2025, reporting an EPS of -$0.95, which missed the consensus estimate of -$0.48 by $0.47. Quarterly revenue was reported to be $12.77 million, above analyst estimates of $3.30 million. With a trailing EPS of -$2.60, NewAmsterdam Pharma's earnings are expected to decrease next year, from ($1.75) to ($1.79) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Annual Report (10-K) Press Release (8-K)NAMS Upcoming EarningsNewAmsterdam Pharma's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get NewAmsterdam Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNAMS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAMS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. NewAmsterdam Pharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.51-$0.20-$0.39Q2 20253-$0.52-$0.34-$0.43Q3 20253-$0.54-$0.35-$0.46Q4 20253-$0.55-$0.35-$0.47FY 202512-$2.12-$1.24-$1.75Q1 20261-$0.54-$0.54-$0.54Q2 20261-$0.53-$0.53-$0.53Q3 20261-$0.54-$0.54-$0.54Q4 20261-$0.56-$0.56-$0.56FY 20264($2.17)($2.17)($2.17) NewAmsterdam Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/14/2025(Estimated)--------2/26/2025Q4 2024-$0.48-$0.95 -$0.47-$0.95$3.30M$12.77M8/7/2024Q2 2024-$0.59-$0.51+$0.08-$0.61$2.20M$2.28M5/8/2024Q1 2024-$0.54-$0.62 -$0.08-$0.18$2.95M$1.40M NewAmsterdam Pharma Earnings - Frequently Asked Questions When is NewAmsterdam Pharma's earnings date? NewAmsterdam Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 14th, 2025 based off last year's report dates. Learn more on NAMS's earnings history. Did NewAmsterdam Pharma beat their earnings estimates last quarter? In the previous quarter, NewAmsterdam Pharma (NASDAQ:NAMS) missed the analysts' consensus estimate of ($0.48) by $0.47 with a reported earnings per share (EPS) of ($0.95). Learn more on analysts' earnings estimate vs. NAMS's actual earnings. How much revenue does NewAmsterdam Pharma generate each year? NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded annual revenue of $45.56 million. How much profit does NewAmsterdam Pharma generate each year? NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded net income of -$176.94 million. NAMS has generated -$2.60 earnings per share over the last four quarters. What is NewAmsterdam Pharma's EPS forecast for next year? NewAmsterdam Pharma's earnings are expected to decrease from ($1.75) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies LNTH Earnings RVMD Earnings BBIO Earnings TGTX Earnings LEGN Earnings SRPT Earnings BPMC Earnings AXSM Earnings NUVL Earnings ADMA Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead This page (NASDAQ:NAMS) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts